The clinical progression follows successful dose escalation cohorts where the maximum tolerated dose has not yet been reached. IDE892 is designed with high selectivity, featuring approximately 1,400-fold greater binding affinity for MTA-PRMT5 complexes compared to SAM-PRMT5, a property intended to widen its therapeutic window. The drug also demonstrates a favorable profile for combination therapy, showing no time-dependent inhibition of major cytochrome P450 enzymes.

Beyond monotherapy, IDEAYA is exploring combination strategies to address tumor heterogeneity. This includes ongoing testing with the MAT2A inhibitor IDE397 and a collaboration with Roche to evaluate IDE892 alongside the pan-RAS inhibitor RG6505. With MTAP deletions occurring in up to 40% of pancreatic ductal adenocarcinoma cases and 15% of non-small cell lung cancers, the company is prioritizing these indications to address a significant clinical gap in precision oncology. Looking ahead, IDEAYA plans to advance a CDKN2A-targeting program into clinical trials by the first half of 2027.